中泰证券(600918) - 2025 Q2 - 季度业绩预告

Overview of Performance Forecast Announcement This section provides an overview of the performance forecast announcement, highlighting key financial projections for the first half of 2025 Important Notice Zhongtai Securities anticipates over 50% growth in H1 2025 net profit and non-recurring net profit - This performance forecast applies to situations where profit is achieved and net profit increases by more than 50% compared to the same period last year[2] 2025 Half-Year Performance Forecast (Preliminary Estimates) | Metric | Amount (Million CNY) | | :--- | :--- | | Net Profit Attributable to Parent Company Shareholders | 722.64 | | Net Profit Attributable to Parent Company Shareholders After Deducting Non-Recurring Gains/Losses | 706.12 | I. Current Period Performance Forecast This section details the company's performance forecast for H1 2025, including projected net profits and their year-on-year changes Performance Forecast Period This forecast covers the period from January 1, 2025, to June 30, 2025 - The performance forecast period is from January 1, 2025, to June 30, 2025[3] Performance Forecast Details The company forecasts significant year-on-year growth in H1 2025 net profit and non-recurring net profit 2025 Half-Year Performance Forecast and Year-on-Year Change | Metric | Estimated Amount (Million CNY) | Year-on-Year Increase (Million CNY) | Year-on-Year Growth Rate | | :--- | :--- | :--- | :--- | | Net Profit Attributable to Parent Company Shareholders | 722.64 | 321.37 | 80.09% | | Net Profit Attributable to Parent Company Shareholders After Deducting Non-Recurring Gains/Losses | 706.12 | 317.40 | 81.65% | Estimated Performance Unaudited by CPA The estimated performance data for this period has not been audited by a certified public accountant - The estimated performance has not been audited by a certified public accountant[3] II. Operating Performance and Financial Status for the Same Period Last Year This section presents the company's key operating performance and financial indicators for the first half of the previous year, 2024 Key Financial Indicators (Same Period Last Year) H1 2024 saw total profit of CNY 471.47 million, net profit of CNY 401.27 million, and EPS of CNY 0.05 Key Financial Indicators for H1 2024 | Metric | Amount (Million CNY) | | :--- | :--- | | Total Profit | 471.47 | | Net Profit Attributable to Parent Company Shareholders | 401.27 | | Net Profit Attributable to Parent Company Shareholders After Deducting Non-Recurring Gains/Losses | 388.72 | | Earnings Per Share | 0.05 (CNY) | III. Primary Reasons for Current Period Performance Increase This section outlines the primary factors contributing to the company's anticipated performance increase in the current period Reasons for Operating Performance Growth H1 2025 growth is driven by core business focus, enhanced competencies, and increased revenues from wealth, investment, and asset management - The company focused on its core responsibilities, striving to enhance five core competencies and four core functions, further improving the quality and efficiency of its operations[6] - Revenues from wealth management, investment, and asset management businesses achieved year-on-year growth[6] Risk Warning and Explanation This section provides important risk warnings and other explanatory matters regarding the preliminary nature of the performance forecast IV. Risk Warning This unaudited forecast has no major uncertainties, but investors should note its preliminary nature - This performance forecast data has not been audited by an accounting firm[7] - The company has no significant uncertainties affecting the accuracy of this performance forecast[7] V. Other Explanatory Matters Preliminary forecast data is subject to the final H1 2025 report; investors are advised to note investment risks - The above forecast data is only preliminary, and the specific accurate financial data will be subject to the company's officially disclosed 2025 half-year report[8] - Investors are kindly requested to pay attention to investment risks[8]